PubMed

An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.

Paz De la Rosa G, Monroy-García A, Mora-García Mde L, Peña CG, Hernández-Montes J, Weiss-Steider B, Gómez-Lim MA.

Virol J. 2009 Jan 6;6:2.PMID: 19126233 [PubMed - indexed for MEDLINE]Related articlesFree article

Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

J Virol. 2009 Jul;83(13):6779-89. Epub 2009 Apr 22.PMID: 19386711 [PubMed - indexed for MEDLINE]Related articlesFree article

Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.

Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA.

Antivir Ther. 2009;14(8):1125-37.PMID: 20032542 [PubMed - indexed for MEDLINE]Related articles

Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.

Thönes N, Müller M.

Virology. 2007 Dec 20;369(2):375-88. Epub 2007 Sep 5.PMID: 17822733 [PubMed - indexed for MEDLINE]Related articles

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. Epub 2009 May 26.PMID: 19470949 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.

Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM.

Intervirology. 2002;45(4-6):300-7.PMID: 12566713 [PubMed - indexed for MEDLINE]Related articles

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1800-5.PMID: 9465097 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.

Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, Kleinschmidt JA.

Vaccine. 2006 Apr 5;24(15):2952-65. Epub 2005 Dec 29.PMID: 16414157 [PubMed - indexed for MEDLINE]Related articles

Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.

Bian T, Wang Y, Lu Z, Ye Z, Zhao L, Ren J, Zhang H, Ruan L, Tian H.

Mol Cancer Ther. 2008 May;7(5):1329-35.PMID: 18483320 [PubMed - indexed for MEDLINE]Related articlesFree article

Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.

Freyschmidt EJ, Alonso A, Hartmann G, Gissmann L.

Antivir Ther. 2004 Aug;9(4):479-89.PMID: 15456078 [PubMed - indexed for MEDLINE]Related articles

Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells.

Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E, Pérez-Martinez G, Perez-Arellano I, Oliveira ML, Ho PL.

Appl Environ Microbiol. 2006 Jan;72(1):745-52.PMID: 16391114 [PubMed - indexed for MEDLINE]Related articlesFree article

Papillomavirus-like particle vaccines.

Schiller JT, Lowy DR.

J Natl Cancer Inst Monogr. 2001;(28):50-4. Review.PMID: 11158207 [PubMed - indexed for MEDLINE]Related articles

Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.

Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP.

J Virol. 2003 Aug;77(15):8386-93.PMID: 12857908 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles.

Xu Y, Zhang H, Xu X.

FEMS Immunol Med Microbiol. 2008 Jan;52(1):99-109. Epub 2007 Nov 7.PMID: 17995958 [PubMed - indexed for MEDLINE]Related articles

Production of human papillomavirus type 16 virus-like particles in transgenic plants.

Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Müller M.

J Virol. 2003 Sep;77(17):9211-20.PMID: 12915537 [PubMed - indexed for MEDLINE]Related articlesFree article

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW, Stern PL, Adams RJ, Roden RB.

Vaccine. 2009 Feb 11;27(7):1040-9. Epub 2008 Dec 16.PMID: 19095032 [PubMed - indexed for MEDLINE]Related articles

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.

Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.

J Med Virol. 2008 May;80(5):841-6.PMID: 18360909 [PubMed - indexed for MEDLINE]Related articles

Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles..

Xu YF, Wang QY, Zhang HT, Han YH, Song GX, Xu XM.

Chin Med J (Engl). 2007 Mar 20;120(6):503-8.PMID: 17439745 [PubMed - indexed for MEDLINE]Related articlesFree article

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.

Vaccine. 2007 Mar 1;25(11):2001-10. Epub 2006 Nov 29.PMID: 17239496 [PubMed - indexed for MEDLINE]Related articles

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.

Seo SH, Jin HT, Park SH, Youn JI, Sung YC.

Vaccine. 2009 Sep 25;27(42):5906-12. Epub 2009 Aug 3.PMID: 19651174 [PubMed - indexed for MEDLINE]Related articles